Relationships between obesity, glycemic control, and cardiovascular risk factors: A pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage

BMC Cardiovascular Disorders

Volumn 14, Issue 1, 2014, Pages

  Vázquez, Luis A ^a   Rodríguez, Ángel ^a   Salvador, Javier ^b   Ascaso, Juan F ^c   Petto, Helmut ^d   Reviriego, Jesús ^a  

^a DAEDALUS Data Decisions and Language SA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Cardiovascular disease; Glycosylated hemoglobin A; Obesity; Observational research; Prevalence; Risk factors

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; SPAIN; TRIGLYCERIDES;

EID: 84920816602     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-14-153     Document Type: Article

References (46)

1. Chen L, Magliano DJ, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2012, 8:228-236.
2. Nathan DM: Navigating the choices for diabetes prevention. N Engl J Med 2010, 362:1533-1535.
3. Allen DB: TODAY-a stark glimpse of tomorrow. N Engl J Med 2012, 366:2315-2316.
4. Polonsky KS: The past 200 years in diabetes. N Engl J Med 2012, 367:1332-1340.
5. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
6. The UK, Prospective Diabetes Study (UKPDS) Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
7. The UK, Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
8. American Diabetes Association: Standards of Medical Care in Diabetes-2014. Diabetes Care 2014, 37:S14-S80.
9. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
10. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351-357.
11. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169.
12. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
13. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
14. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
15. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M: Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008, 31(Suppl 2):S155-S160.
16. Conus F, Rabasa-Lhoret R, Peronnet F: Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 2007, 32:4-12.
17. Rodríguez A, Ciprés L, Tofé S, Polavieja P, Reviriego J: Clinical evaluation of combined therapy for type 2 diabetes. Curr Med Res Opin 2010, 26:1171-1183.
18. Rodríguez A, Calle A, Vázquez L, Chacón F, Polavieja P, Reviriego J, CADiNI Study Group: Blood glucose control and quality of health care in noninsulin-treated patients with Type 2 diabetes in Spain: a retrospective and cross-sectional observational study. Diabet Med 2011, 28:731-740.
19. Rodríguez Bernardino A, García Polavieja P, Reviriego Fernández J, Serrano Ríos M: [Prevalence of metabolic syndrome and consistency in its diagnosis in type 2 diabetic patients in Spain]. Endocrinol Nutr 2010, 57:60-70.
20. Dilla T, Valladares A, Nicolay C, Salvador J, Reviriego J, Costi M: Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study. Appl Health Econ Health Policy 2012, 10:417-430.
21. Costi M, Dilla T, Reviriego J, Castell C, Goday A: Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. Acta Diabetol 2010, 47:169-175.
22. Gomis R, Artola S, Conthe P, Vidal J, Casamor R, Font B, Investigadores del Grupo de Estudio OBEDIA: Prevalence of type 2 diabetes mellitus in overweight or obese patients outpatients in Spain. OBEDIA Study. Med Clin (Barc) 2014, 142:485-492.
23. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Wild SH, Sattar N, Scottish Diabetes Research Network Epidemiology Group: Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 2011, 54:3003-3006.
24. Mata-Cases M, Mauricio D, Vinagre I, Morros R, Hermosilla E, Fina F, Rosell-Murphy M, Castell C, Franch-Nadal J, Bolíbar B: Treatment of hyperglycaemia in type 2 diabetic patients in a primary care population database in a Mediterranean area (Catalonia, Spain). J Diabetes Metab 2014, 5:2. http://dx.doi.org/10.4172/2155-6156.1000338.
25. Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban B: Prevalencia de obesidad en España. Med Clin (Barc) 2005, 125:460-466.
26. Casanueva FF, Moreno B, Rodriguez-Azeredo R, Massien C, Conthe P, Formiguera X, Barrios V, Balkau B: Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol (Oxf ) 2010, 73:35-40.
27. Aranceta J, Perez Rodrigo C, Serra Majem L, Ribas Barba L, Quiles Izquierdo J, Vioque J, Tur Mari J, Mataix Verdu J, Llopis Gonzalez J, Tojo R, Foz Sala M: Prevalencia de la obesidad en España: resultados del estudio SEEDO 2000. Med Clin (Barc) 2003, 120:608-612.
28. Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F: Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes Rev 2012, 13:388-392.
29. Pinhas-Hamiel O, Zeitler P: The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005, 146:693-700.
30. Power C, Thomas C: Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort. Diabetes Care 2011, 34:1986-1991.
31. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H: Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006, 84:427-433.
32. Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, Casamitjana R, Castano L, Castell C, Catala M, Delgado E, Franch J, Gaztambide S, Girbes J, Gomis R, Gutierrez G, Lopez-Alba A, Martinez-Larrad MT, Menendez E, Mora-Peces I, Ortega E, Pascual-Manich G, Rojo-Martinez G, Serrano-Rios M, Valdes S, Vazquez JA, Vendrell J: Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012, 55:88-93.
33. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, Sun C, Cheung M, Viikari JS, Dwyer T, Raitakari OT: Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011, 365:1876-1885.
34. Capewell S, Buchan I: Why have sustained increases in obesity and type 2 diabetes not offset declines in cardiovascular mortality over recent decades in Western countries? Nutr Metab Cardiovasc Dis 2012, 22:307-311.
35. Preston SH: Deadweight?-The influence of obesity on longevity. N Engl J Med 2005, 352:1135-1137.
36. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, Castell C, Franch-Nadal J, Bolibar B, Mauricio D: Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 2012, 35:774-779.
37. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, GrimmRH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl JMed 2008, 358:2545-2559.
38. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
39. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, VitekME, Henderson WG, Huang GD, VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
40. Grau M, Elosua R, Cabrera de Leon A, Guembe MJ, Baena-Diez JM, Vega Alonso T, Javier Felix F, Zorrilla B, Rigo F, Lapetra J, Gavrila D, Segura A, Sanz H, Fernandez-Berges D, Fito M, Marrugat J: [Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study]. Rev Esp Cardiol 2011, 64:295-304.
41. Stefan N, Häring HU, Hu FB, Schulze MB: Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013, 1:152-162.
42. Jais A, Einwallner E, Sharif O, Gossens K, Lu TT, Soyal SM, Medgyesi D, Neureiter D, Paier-Pourani J, Dalgaard K, Duvigneau JC, Lindroos-Christensen J, Zapf TC, Amann S, Saluzzo S, Jantscher F, Stiedl P, Todoric J, Martins R, Oberkofler H, Müller S, Hauser-Kronberger C, Kenner L, Casanova E, Sutterlüty-Fall H, Bilban M, Miller K, Kozlov AV, Krempler F, Knapp S, et al: Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014, 158:25-40.
43. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association, European Association for the Study of Diabetes: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
44. Fagot-Campagna A, Balkau B, Simon D, Ducimetière P, Eschwège E: Is insulin an independent risk factor for hypertension? The Paris Prospective Study. Int J Epidemiol 1997, 26:542-550.
45. Tseng CH: Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus. Arch Intern Med 2006, 166:1184-1189.
46. Phillips CM: Metabolically healthy obesity: Definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013, 14:219-227.